Display options
Cite
Thomas PB, Jeffery P, Gahete MD, et al. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. PeerJ. 2021;9:e10280doi: 10.7717/peerj.10280.
Thomas, P. B., Jeffery, P., Gahete, M. D., Whiteside, E., Walpole, C., Maugham, M., Jovanovic, L., Gunter, J., Williams, E., Nelson, C., Herington, A., Luque, R. M., Veedu, R., Chopin, L. K., & Seim, I. (2021). The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. PeerJ, 9e10280. https://doi.org/10.7717/peerj.10280
Thomas, Patrick B, et al. "The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype." PeerJ vol. 9 (2021): e10280. doi: https://doi.org/10.7717/peerj.10280
Thomas PB, Jeffery P, Gahete MD, Whiteside E, Walpole C, Maugham M, Jovanovic L, Gunter J, Williams E, Nelson C, Herington A, Luque RM, Veedu R, Chopin LK, Seim I. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. PeerJ. 2021 Feb 01;9:e10280. doi: 10.7717/peerj.10280. eCollection 2021. PMID: 33585078; PMCID: PMC7860111.
Copy Download .nbib Format: NLM
Share it on

PeerJ. 2021 Feb 01;9:e10280. doi: 10.7717/peerj.10280. eCollection 2021.

The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.

PeerJ

Patrick B Thomas, Penny Jeffery, Manuel D Gahete, Eliza Whiteside, Carina Walpole, Michelle Maugham, Lidija Jovanovic, Jennifer Gunter, Elizabeth Williams, Colleen Nelson, Adrian Herington, Raul M Luque, Rakesh Veedu, Lisa K Chopin, Inge Seim

Affiliations

  1. Ghrelin Research Group, Translational Research Institute, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  2. Comparative and Endocrine Biology Laboratory, Translational Research Institute, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  3. Australian Prostate Cancer Research Centre - Queensland, Queensland University of Technology, Brisbane, Queensland, Australia.
  4. Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain.
  5. Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain.
  6. Hospital Universitario Reina Sofía (HURS), Cordoba, Spain.
  7. Campus de Excelencia Internacional Agroalimentario (ceiA3), Cordoba, Spain.
  8. CIBER de la Fisiopatología de la Obesidad y Nutrición (CIBERobn), Cordoba, Spain.
  9. Centre for Health Research, University of Southern Queensland, Toowoomba, Queensland, Australia.
  10. Institute for Life Sciences and the Environment, University of Southern Queensland, Toowoomba, Queensland, Australia.
  11. Centre for Comparative Genomics, Murdoch University, Perth, Western Australia, Australia.
  12. Integrative Biology Laboratory, College of Life Sciences, Nanjing Normal University, Nanjing, China.

PMID: 33585078 PMCID: PMC7860111 DOI: 10.7717/peerj.10280

Abstract

It is now appreciated that long non-coding RNAs (lncRNAs) are important players in orchestrating cancer progression. In this study we characterized

©2021 Thomas et al.

Keywords: Antisense transcript; Gene expression; Long non-coding RNA; Prostate cancer; Tumour growth; lncRNA

Conflict of interest statement

The authors declare there are no competing interests.

References

  1. Oncogene. 2015 Apr 2;34(14):1745-57 - PubMed
  2. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):14-20 - PubMed
  3. Genome Res. 2012 Sep;22(9):1775-89 - PubMed
  4. Nature. 2011 Apr 7;472(7341):120-4 - PubMed
  5. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  6. Horm Cancer. 2015 Jun;6(2-3):120-7 - PubMed
  7. Nat Med. 2015 Nov;21(11):1253-61 - PubMed
  8. Mol Cell Biochem. 2007 Dec;306(1-2):255-60 - PubMed
  9. Mol Cell Biol. 2016 May 02;36(10):1509-25 - PubMed
  10. Cell Rep. 2013 Jun 27;3(6):2127-41 - PubMed
  11. RNA Biol. 2015;12(6):628-42 - PubMed
  12. Cell Rep. 2014 Oct 23;9(2):741-51 - PubMed
  13. BJU Int. 2015 Jul;116(1):17-29 - PubMed
  14. Nat Rev Mol Cell Biol. 2013 Nov;14(11):699-712 - PubMed
  15. Cancer Lett. 2016 Dec 1;383(1):125-134 - PubMed
  16. Ther Adv Med Oncol. 2017 May;9(5):307-318 - PubMed
  17. Nat Struct Mol Biol. 2015 Jan;22(1):5-7 - PubMed
  18. Genes Dev. 2011 Sep 15;25(18):1915-27 - PubMed
  19. Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 - PubMed
  20. Genome Res. 2013 Mar;23(3):486-96 - PubMed
  21. Cancer Res. 2012 Jan 1;72(1):122-32 - PubMed
  22. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  23. JAMA Oncol. 2015 Jul;1(4):505-27 - PubMed
  24. Cancer Res. 1994 May 15;54(10):2577-81 - PubMed
  25. Transl Cancer Res. 2017 Feb;6(Suppl 1):S47-S50 - PubMed
  26. In Vivo. 2001 Mar-Apr;15(2):157-62 - PubMed
  27. Nat Protoc. 2009;4(1):44-57 - PubMed
  28. Prostate. 2005 Sep 15;65(1):35-43 - PubMed
  29. G3 (Bethesda). 2017 Jun 7;7(6):1731-1741 - PubMed
  30. Med Oncol. 2015 Jan;32(1):426 - PubMed
  31. Am J Pathol. 2011 Jul;179(1):400-10 - PubMed
  32. Oncol Lett. 2014 Oct;8(4):1788-1792 - PubMed
  33. Cancer Cell. 2010 Jul 13;18(1):11-22 - PubMed
  34. Oncotarget. 2016 Apr 5;7(14):17631-40 - PubMed
  35. Nature. 2014 Jan 30;505(7485):635-40 - PubMed
  36. Nat Genet. 2016 Jan;48(1):12-21 - PubMed
  37. Asian J Androl. 2014 May-Jun;16(3):407-12 - PubMed
  38. Neoplasia. 2007 Feb;9(2):166-80 - PubMed
  39. Nat Biotechnol. 2017 Apr 11;35(4):314-316 - PubMed
  40. J Immunol. 2005 May 15;174(10):6477-89 - PubMed
  41. Proc Natl Acad Sci U S A. 2016 May 31;113(22):6259-64 - PubMed
  42. Nucleic Acids Res. 2015 Apr 20;43(7):e47 - PubMed
  43. PLoS Genet. 2012;8(7):e1002841 - PubMed
  44. EMBO Mol Med. 2015 Apr 20;7(7):878-94 - PubMed
  45. Elife. 2014 Sep 16;3:e03523 - PubMed
  46. Prostate. 2013 Feb 15;73(3):306-15 - PubMed
  47. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):807-12 - PubMed
  48. Mol Cancer Res. 2013 Jun;11(6):568-78 - PubMed
  49. Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1412-7 - PubMed
  50. Mol Endocrinol. 2011 Apr;25(4):621-34 - PubMed
  51. BMC Cancer. 2005 May 13;5:45 - PubMed
  52. Biochem Cell Biol. 2017 Oct;95(5):578-584 - PubMed
  53. Oncogene. 2014 Oct 23;33(43):5053-64 - PubMed
  54. Biomed Pharmacother. 2016 Jul;81:25-30 - PubMed
  55. Genome Biol. 2010;11(3):R25 - PubMed
  56. Genome Res. 2003 Nov;13(11):2498-504 - PubMed
  57. Nat Rev Clin Oncol. 2018 Feb;15(2):81-94 - PubMed
  58. Transl Androl Urol. 2015 Jun;4(3):365-80 - PubMed
  59. Nature. 2012 Jul 12;487(7406):239-43 - PubMed
  60. Bioinformatics. 2007 Oct 15;23(20):2651-9 - PubMed
  61. Tumour Biol. 2015 Aug;36(8):5753-5 - PubMed
  62. Bioinformatics. 2007 Jul 15;23(14):1846-7 - PubMed
  63. Mol Cancer. 2009 Aug 11;8:61 - PubMed
  64. Oncotarget. 2017 Jun 27;8(26):43035-43047 - PubMed
  65. Cell Rep. 2018 Apr 3;23(1):297-312.e12 - PubMed
  66. Methods. 2001 Dec;25(4):402-8 - PubMed
  67. Cell. 2015 Nov 5;163(4):1011-25 - PubMed
  68. Brief Bioinform. 2019 Sep 27;20(5):1853-1864 - PubMed
  69. PLoS One. 2014 Jan 28;9(1):e84611 - PubMed
  70. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 - PubMed
  71. Nat Genet. 2013 Nov;45(11):1392-8 - PubMed
  72. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  73. Mol Ther. 2017 May 3;25(5):1069-1075 - PubMed
  74. FEBS Lett. 2013 Dec 11;587(24):3892-7 - PubMed
  75. Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368 - PubMed
  76. Int J Oncol. 2019 Dec;55(6):1223-1236 - PubMed
  77. Cancer Cell. 2017 Oct 9;32(4):474-489.e6 - PubMed
  78. Sci Rep. 2017 Jan 19;7:40729 - PubMed
  79. Br J Cancer. 2004 Feb 9;90(3):720-7 - PubMed
  80. Oncotarget. 2017 Apr 25;8(17):29395-29405 - PubMed
  81. Asian J Androl. 2016 Jul-Aug;18(4):543-8 - PubMed
  82. Science. 2017 Jan 6;355(6320): - PubMed
  83. Mol Ther. 2019 Oct 2;27(10):1718-1725 - PubMed
  84. Science. 2009 May 8;324(5928):787-90 - PubMed
  85. Int J Oncol. 2013 Aug;43(2):566-74 - PubMed
  86. Prostate. 2017 May;77(6):654-671 - PubMed
  87. Biomed Pharmacother. 2016 Feb;77:92-7 - PubMed

Publication Types